Characteristics of patients analyzed longitudinally during the posttransplantation follow-up
| UPN . | Sex . | Age (y) . | Diagnosis . | Refined DFI* . | Conditioning regimen† . | GVHD prophylaxis‡ . | Predicted NK alloreactivity§ . | Graft source . | CD3+ cells infused/kg × 106 . | NK cells infused/kg × 106 . |
|---|---|---|---|---|---|---|---|---|---|---|
| OSR 1 | M | 33 | sAML | Low | Thio-Treo-Flu | PT-Cy-sirolimus-MMF | Yes (C1) | PB | 135.28 | 19.9 |
| OSR 2 | M | 69 | sAML | High | Thio-Treo-Flu|| | PT-Cy-sirolimus-MMF | No | PB | 250 | 17.32 |
| OSR 3 | F | 24 | HL | High | Thio-Treo-Flu | PT-Cy-sirolimus-MMF | No | PB | 194.3 | 9.18 |
| OSR 4 | F | 62 | AML | High | Thio-Treo-Flu | PT-Cy-sirolimus-MMF | Yes (C1) | PB | 267.89 | 17.13 |
| OSR 5 | M | 57 | sAML | Intermediate | Thio-Treo-Flu | PT-Cy-sirolimus-MMF | Yes (C1) | PB | 174.91 | 21.09 |
| OSR 6 | F | 45 | AML | High | Thio-Treo-Flu | PT-Cy-sirolimus-MMF | No | BM | 31.55 | 1.66 |
| OSR 7 | M | 34 | NHL | Very high | Thio-Treo-Flu | PT-Cy-sirolimus-MMF | No | PB | 81.9 | 13.09 |
| OSR 8 | F | 76 | MDS | High | Thio-Treo-Flu|| | PT-Cy-sirolimus-MMF | No | PB | 326.4 | 17.2 |
| OSR 9 | M | 63 | AML | High | Thio-Treo-Flu | PT-Cy-sirolimus-MMF | Yes (Bw4) | PB | 98.57 | 8.02 |
| OSR 10 | F | 65 | AML | High | Thio-Treo-Flu | PT-Cy-sirolimus-MMF | Yes (C2) | PB | 98.86 | 16.58 |
| JHU 1 | M | 27 | AML | High | Flu-CTX-TBI 2 Gy | PT-Cy-tacrolimus-MMF | Yes (C2) | BM | 85.5 | 8.2 |
| JHU 2 | M | 67 | CML | High | Flu-CTX-TBI 2 Gy | PT-Cy-tacrolimus-MMF | No | BM | 157.6 | 5.3 |
| JHU 3 | M | 56 | NHL | Very high | Flu-CTX-TBI 2 Gy | PT-Cy-tacrolimus-MMF | No | BM | 73.3 | 6.3 |
| JHU 4 | M | 58 | sAML | Very high | Flu-CTX-TBI 2 Gy | PT-Cy-tacrolimus-MMF | Yes (C1) | BM | 199.2 | 26.2 |
| JHU 5 | M | 69 | AML | Very high | Flu-CTX-TBI 2 Gy | PT-Cy-tacrolimus-MMF | Yes (C2) | BM | 42.5 | 2.95 |
| JHU 6 | M | 33 | ALL | High | Flu-CTX-TBI 2 Gy | PT-Cy-sirolimus-MMF | No | BM | 41.9 | 5.50 |
| JHU 7 | M | 65 | AML | High | Flu-CTX-TBI 2 Gy | PT-Cy-tacrolimus-MMF | Yes (Bw4) | BM | 72.0 | 6.83 |
| UPN . | Sex . | Age (y) . | Diagnosis . | Refined DFI* . | Conditioning regimen† . | GVHD prophylaxis‡ . | Predicted NK alloreactivity§ . | Graft source . | CD3+ cells infused/kg × 106 . | NK cells infused/kg × 106 . |
|---|---|---|---|---|---|---|---|---|---|---|
| OSR 1 | M | 33 | sAML | Low | Thio-Treo-Flu | PT-Cy-sirolimus-MMF | Yes (C1) | PB | 135.28 | 19.9 |
| OSR 2 | M | 69 | sAML | High | Thio-Treo-Flu|| | PT-Cy-sirolimus-MMF | No | PB | 250 | 17.32 |
| OSR 3 | F | 24 | HL | High | Thio-Treo-Flu | PT-Cy-sirolimus-MMF | No | PB | 194.3 | 9.18 |
| OSR 4 | F | 62 | AML | High | Thio-Treo-Flu | PT-Cy-sirolimus-MMF | Yes (C1) | PB | 267.89 | 17.13 |
| OSR 5 | M | 57 | sAML | Intermediate | Thio-Treo-Flu | PT-Cy-sirolimus-MMF | Yes (C1) | PB | 174.91 | 21.09 |
| OSR 6 | F | 45 | AML | High | Thio-Treo-Flu | PT-Cy-sirolimus-MMF | No | BM | 31.55 | 1.66 |
| OSR 7 | M | 34 | NHL | Very high | Thio-Treo-Flu | PT-Cy-sirolimus-MMF | No | PB | 81.9 | 13.09 |
| OSR 8 | F | 76 | MDS | High | Thio-Treo-Flu|| | PT-Cy-sirolimus-MMF | No | PB | 326.4 | 17.2 |
| OSR 9 | M | 63 | AML | High | Thio-Treo-Flu | PT-Cy-sirolimus-MMF | Yes (Bw4) | PB | 98.57 | 8.02 |
| OSR 10 | F | 65 | AML | High | Thio-Treo-Flu | PT-Cy-sirolimus-MMF | Yes (C2) | PB | 98.86 | 16.58 |
| JHU 1 | M | 27 | AML | High | Flu-CTX-TBI 2 Gy | PT-Cy-tacrolimus-MMF | Yes (C2) | BM | 85.5 | 8.2 |
| JHU 2 | M | 67 | CML | High | Flu-CTX-TBI 2 Gy | PT-Cy-tacrolimus-MMF | No | BM | 157.6 | 5.3 |
| JHU 3 | M | 56 | NHL | Very high | Flu-CTX-TBI 2 Gy | PT-Cy-tacrolimus-MMF | No | BM | 73.3 | 6.3 |
| JHU 4 | M | 58 | sAML | Very high | Flu-CTX-TBI 2 Gy | PT-Cy-tacrolimus-MMF | Yes (C1) | BM | 199.2 | 26.2 |
| JHU 5 | M | 69 | AML | Very high | Flu-CTX-TBI 2 Gy | PT-Cy-tacrolimus-MMF | Yes (C2) | BM | 42.5 | 2.95 |
| JHU 6 | M | 33 | ALL | High | Flu-CTX-TBI 2 Gy | PT-Cy-sirolimus-MMF | No | BM | 41.9 | 5.50 |
| JHU 7 | M | 65 | AML | High | Flu-CTX-TBI 2 Gy | PT-Cy-tacrolimus-MMF | Yes (Bw4) | BM | 72.0 | 6.83 |
ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; Bw4, HLA-Bw4; C1, HLA-C group 1; C2, HLA-C group 2; CML, chronic myeloid leukemia; DRI, Disease Risk Index; F, female; HL, Hodgkin lymphoma; M, male; MDS, myelodysplastic syndrome; NHL, non-Hodgkin lymphoma; sAML, secondary acute myeloid leukemia.
DRI calculated according to Armand et al.49
Conditioning regimens: Flu-CTX-TBI 2 Gy, fludarabine (30 mg/m2/d on days −6 to −2), cyclophosphamide (14.5 mg/kg/d on days −6 and −5), and 200 cGy of TBI on day −1; Thio-Treo-Flu, thiotepa (5 mg/kg/d on days −3 and −2), treosulfan (14 g/m2/d on days −6 to −4), and fludarabine (30 mg/m2/d on days −6 to −2).
GVHD prophylaxis: PT-Cy-sirolimus-MMF, cyclophosphamide (50 mg/kg) on days +3 and +4, sirolimus (monitored to maintain a target therapeutic plasma level of 5-15 ng/mL) from day +5, mycophenolate mofetil (10 mg/kg 3 times daily) from day 5; PT-Cy-tacrolimus-MMF, cyclophosphamide (50 mg/kg) on days +3 and +4, tacrolimus (monitored to maintain a target therapeutic plasma level of 5-15 ng/mL) from day +5, and mycophenolate mofetil (15 mg/kg twice daily) from day 5.
Predicted NK alloreactivity: exclusively in the graft-versus-leukemia reaction, calculated according to the Perugia algorithm as the absence in the patient of killer cell immunoglobulin-like receptor ligands (either Bw4, C1, or C2) present in the donor.
These patients received a reduced dose of thiotepa (3 mg/kg) and treosulfan (12 gram/m2) because of old age.